{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:53:53Z","timestamp":1795024433710,"version":"4.10.2"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ajo.2021.01.019","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T11:18:11Z","timestamp":1611919091000},"page":"262-269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3904-2625","authenticated-orcid":false,"given":"Arthur J.","family":"Sit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divakar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Kazemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0205-0517","authenticated-orcid":false,"given":"Hayley","family":"McKee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratap","family":"Challa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy C.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Kopczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Heah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ajo.2021.01.019_bib0001","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"on behalf the Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States","volume":"122","author":"Congdon","year":"2004","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2021.01.019_bib0002","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMra0804630","article-title":"Primary open-angle glaucoma","volume":"360","author":"Kwon","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ajo.2021.01.019_bib0003","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/09286580600681339","article-title":"Causal inference in primary open angle glaucoma: specific discussion on intraocular pressure","volume":"13","author":"Bahrami","year":"2006","journal-title":"Ophthalmic Epidemiol"},{"issue":"10","key":"10.1016\/j.ajo.2021.01.019_bib0004","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2021.01.019_bib0005","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"Suppl 15","key":"10.1016\/j.ajo.2021.01.019_bib0006","first-page":"S279","article-title":"Current therapeutic options and treatments in development for the management of primary open-angle glaucoma","volume":"23","author":"Liebmann","year":"2017","journal-title":"Am J Manag Care"},{"issue":"1","key":"10.1016\/j.ajo.2021.01.019_bib0007","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41433-019-0633-6","article-title":"Treatment choices for newly diagnosed primary open angle and ocular hypertension patients","volume":"34","author":"Garg","year":"2020","journal-title":"Eye (Lond)"},{"issue":"1","key":"10.1016\/j.ajo.2021.01.019_bib0008","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ophtha.2015.10.053","article-title":"Primary open-angle glaucoma preferred practice pattern guidelines","volume":"123","author":"Prum","year":"2016","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.ajo.2021.01.019_bib0009","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0161-6420(01)00873-9","article-title":"et al on behalf of the CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery","volume":"108","author":"Lichter","year":"2001","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2021.01.019_bib0010","first-page":"233","article-title":"Compliance in patients prescribed eyedrops for glaucoma","volume":"26","author":"Patel","year":"1995","journal-title":"Ophthalmic Surg"},{"issue":"5","key":"10.1016\/j.ajo.2021.01.019_bib0011","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.ophtha.2004.12.026","article-title":"Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?","volume":"112","author":"Robin","year":"2005","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2021.01.019_bib0012","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ajo.2007.06.012","article-title":"Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use","volume":"144","author":"Robin","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"Suppl 1","key":"10.1016\/j.ajo.2021.01.019_bib0013","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/j.survophthal.2008.08.010","article-title":"Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction","volume":"53","author":"Toris","year":"2008","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2021.01.019_bib0014","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/ICU.0b013e32834ff23e","article-title":"Current understanding of conventional outflow dysfunction in glaucoma","volume":"23","author":"Stamer","year":"2012","journal-title":"Curr Opin Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2021.01.019_bib0015","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/archopht.1991.01080060143044","article-title":"Outflow facility and its response to pilocarpine decline in aging rhesus monkeys","volume":"109","author":"Gabelt","year":"1991","journal-title":"Arch Ophthalmol"},{"issue":"1-2","key":"10.1016\/j.ajo.2021.01.019_bib0016","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1089\/jop.2017.0023","article-title":"Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma","volume":"34","author":"Lin","year":"2018","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ajo.2021.01.019_bib0017","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/108076802317233216","article-title":"Effects of multiple dosing of epinephrine on aqueous humor dynamics in human eyes","volume":"18","author":"Wang","year":"2002","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ajo.2021.01.019_bib0018","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/jop.1994.10.241","article-title":"Adrenergic regulation of aqueous outflow","volume":"10","author":"Erickson","year":"1994","journal-title":"J Ocul Pharmacol"},{"issue":"11","key":"10.1016\/j.ajo.2021.01.019_bib0019","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1001\/archopht.1978.03910060433007","article-title":"The mechanism of timolol in lowering intraocular pressure in the normal eye","volume":"96","author":"Coakes","year":"1978","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2021.01.019_bib0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0014-4835(78)90083-0","article-title":"A fluorophotometric study of the effect of topical timolol on aqueous humor dynamics","volume":"27","author":"Yablonski","year":"1978","journal-title":"Exp Eye Res"},{"issue":"Suppl 4","key":"10.1016\/j.ajo.2021.01.019_bib0021","doi-asserted-by":"crossref","first-page":"S347","DOI":"10.1016\/S0039-6257(01)00213-2","article-title":"Mechanism of action of bimatoprost (Lumigan)","volume":"45","author":"Brubaker","year":"2001","journal-title":"Surv Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2021.01.019_bib0022","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1001\/archopht.1993.01090100059027","article-title":"The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes","volume":"111","author":"Ziai","year":"1993","journal-title":"Arch Ophthalmol"},{"issue":"5-6","key":"10.1016\/j.ajo.2021.01.019_bib0023","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/BF00143664","article-title":"Out-flow pressure, minute volume and resistance of the anterior chamber flow in man","author":"Goldmann","year":"1951","journal-title":"Doc Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2021.01.019_bib0024","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.exer.2003.07.002","article-title":"Goldmann's equation and clinical measures of aqueous dynamics","volume":"78","author":"Brubaker","year":"2004","journal-title":"Exp Eye Res"},{"issue":"6","key":"10.1016\/j.ajo.2021.01.019_bib0025","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1586\/eop.11.65","article-title":"Rho kinase inhibitors for treatment of glaucoma","volume":"6","author":"Mandell","year":"2011","journal-title":"Expert Rev Ophthalmol"},{"key":"10.1016\/j.ajo.2021.01.019_bib0026","first-page":"883","article-title":"An emerging treatment option for glaucoma: Rho kinase inhibitors","volume":"8","author":"Wang","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ajo.2021.01.019_bib0027","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.exer.2016.08.023","article-title":"Role of the Rho GTPase\/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: bench to bedside research","volume":"158","author":"Rao","year":"2017","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ajo.2021.01.019_bib0028","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","volume":"186","author":"Serle","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"14","key":"10.1016\/j.ajo.2021.01.019_bib0029","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1167\/iovs.16-20189","article-title":"Netarsudil increases outflow facility in human eyes through multiple mechanisms","volume":"57","author":"Ren","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2021.01.019_bib0030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejphar.2016.04.002","article-title":"Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes","volume":"787","author":"Li","year":"2016","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.ajo.2021.01.019_bib0031","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/IJG.0b013e3182952213","article-title":"Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes","volume":"24","author":"Wang","year":"2015","journal-title":"J Glaucoma"},{"issue":"3","key":"10.1016\/j.ajo.2021.01.019_bib0032","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/jop.2014.0146","article-title":"Effect of AR-13324 on episcleral venous pressure in Dutch belted rabbits","volume":"31","author":"Kiel","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.ajo.2021.01.019_bib0033","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1089\/jop.2017.0138","article-title":"The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans","volume":"34","author":"Kazemi","year":"2018","journal-title":"J Ocul Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ajo.2021.01.019_bib0034","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/archopht.1950.00910020209003","article-title":"Tonographic method for measuring the facility and rate of aqueous flow in human eyes","volume":"44","author":"Grant","year":"1950","journal-title":"Arch Ophthal"},{"issue":"1","key":"10.1016\/j.ajo.2021.01.019_bib0035","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1167\/iovs.16-20754","article-title":"Comparison of aqueous outflow facility measurement by pneumatonography and digital Schi\u00f8tz tonography","volume":"58","author":"Kazemi","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"10.1016\/j.ajo.2021.01.019_bib0036","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0002-9394(37)90425-2","article-title":"Contribution to the theory and practice of tonometry","volume":"20","author":"Friedenwald","year":"1937","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2021.01.019_bib0037","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.exer.2011.03.018","article-title":"A novel method for computerized measurement of episcleral venous pressure in humans","volume":"92","author":"Sit","year":"2011","journal-title":"Exp Eye Res"},{"issue":"1","key":"10.1016\/j.ajo.2021.01.019_bib0038","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archopht.121.1.48","article-title":"Komaroff E on behalf of the Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial","volume":"121","author":"Leske","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2021.01.019_bib0039","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ajo.2019.03.002","article-title":"Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 study","volume":"204","author":"Khouri","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"13","key":"10.1016\/j.ajo.2021.01.019_bib0040","first-page":"2772","article-title":"Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells","volume":"38","author":"Weinreb","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.ajo.2021.01.019_bib0041","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/archopht.119.8.1165","article-title":"Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment","volume":"119","author":"Gaton","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2021.01.019_bib0042","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archopht.117.6.794","article-title":"Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway","volume":"117","author":"Sagara","year":"1999","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2021.01.019_bib0043","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1167\/iovs.05-1627","article-title":"The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey","volume":"47","author":"Nilsson","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.ajo.2021.01.019_bib0044","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ogla.2020.05.008","article-title":"One year of netarsudil and latanoprost fixed-dose combination for elevated intraocular pressure: phase 3, randomized MERCURY-1 study","volume":"3","author":"Brubaker","year":"2020","journal-title":"Ophthalmol Glaucoma"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939421000404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939421000404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:42:23Z","timestamp":1762080143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939421000404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":44,"alternative-id":["S0002939421000404"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2021.01.019","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2021.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}